PE20121171A1 - Metodo, kit, plasmido y composicion para inducir una respuesta inmunitaria contra el virus del dengue basandose en vacunas de adn y virus quimericos - Google Patents
Metodo, kit, plasmido y composicion para inducir una respuesta inmunitaria contra el virus del dengue basandose en vacunas de adn y virus quimericosInfo
- Publication number
- PE20121171A1 PE20121171A1 PE2012000411A PE2012000411A PE20121171A1 PE 20121171 A1 PE20121171 A1 PE 20121171A1 PE 2012000411 A PE2012000411 A PE 2012000411A PE 2012000411 A PE2012000411 A PE 2012000411A PE 20121171 A1 PE20121171 A1 PE 20121171A1
- Authority
- PE
- Peru
- Prior art keywords
- dengue virus
- viruses
- composition
- dna vaccines
- chemeric
- Prior art date
Links
- 241000725619 Dengue virus Species 0.000 title abstract 4
- 229960005486 vaccine Drugs 0.000 title abstract 3
- 241000700605 Viruses Species 0.000 title abstract 2
- 230000028993 immune response Effects 0.000 title 1
- 239000013612 plasmid Substances 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 241000710829 Dengue virus group Species 0.000 abstract 1
- 102000013566 Plasminogen Human genes 0.000 abstract 1
- 108010051456 Plasminogen Proteins 0.000 abstract 1
- 108010076504 Protein Sorting Signals Proteins 0.000 abstract 1
- 239000012190 activator Substances 0.000 abstract 1
- 238000010276 construction Methods 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
- 229960001515 yellow fever vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
REFERIDA A UNA COMPOSICION DE VACUNA CONTRA EL VIRUS DEL DENGUE QUE COMPRENDE: a) VACUNAS DE ADN CONTRA LOS CUATRO SEROTIPOS DEL VIRUS DEL DENGUE A PARTIR DE LA CONSTRUCCION DE DIFERENTES PLASMIDOS RECOMBINANTES QUE CONTIENEN LOS GENES QUE CODIFICAN PARA LAS PROTEINAS E DE CADA SEROTIPO DEL VIRUS DEL DENGUE, O SOLO LAS SECUENCIAS CORRESPONDIENTES A LOS DOMINIOS III DE ESTAS PROTEINAS, TODAS FUSIONADAS A LA SECUENCIA QUE CODIFICA PARA EL PEPTIDO SENAL DEL ACTIVADOR DEL PLASMINOGENO TISULAR HUMANO (t-PA), b) VIRUS QUIMERICOS QUE COMPRENDEN EL VIRUS DE LA VACUNA DE LA FIEBRE AMARILLA 17D MODIFICADO, CON LA SUSTITUCION DE LAS SECUENCIAS QUE CODIFICAN PARA LAS PROTEINAS prM Y E DE LA FEBRE AMARILLA POR SECUENCIAS QUE CODIFICAN PARA LAS PROTEINAS prM Y E DEL VIRUS DEL DENGUE DE DIFERENTES SEROTIPOS Y c) UN VEHICULO FARMACEUTICAMENTE ACEPTABLE
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0904020A BRPI0904020B8 (pt) | 2009-10-01 | 2009-10-01 | composição vacinal contra o vírus da dengue, e, kit |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20121171A1 true PE20121171A1 (es) | 2012-08-30 |
Family
ID=43825448
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2016001214A PE20161094A1 (es) | 2009-10-01 | 2010-08-01 | Metodo, kit, plasmido y composicion para inducir una respuesta inmunitaria contra el virus del dengue basandose en vacunas de adn y virus quimericos |
PE2012000411A PE20121171A1 (es) | 2009-10-01 | 2010-08-01 | Metodo, kit, plasmido y composicion para inducir una respuesta inmunitaria contra el virus del dengue basandose en vacunas de adn y virus quimericos |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2016001214A PE20161094A1 (es) | 2009-10-01 | 2010-08-01 | Metodo, kit, plasmido y composicion para inducir una respuesta inmunitaria contra el virus del dengue basandose en vacunas de adn y virus quimericos |
Country Status (10)
Country | Link |
---|---|
US (1) | US10357558B2 (es) |
EP (1) | EP2484376A4 (es) |
CN (1) | CN102711817B (es) |
BR (1) | BRPI0904020B8 (es) |
CL (1) | CL2012000783A1 (es) |
CO (1) | CO6541529A2 (es) |
CU (1) | CU24060B1 (es) |
EC (1) | ECSP12012131A (es) |
PE (2) | PE20161094A1 (es) |
WO (1) | WO2011038473A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3177574A1 (en) * | 2013-03-15 | 2014-09-25 | Takeda Vaccines, Inc. | Compositions and methods for dengue virus chimeric constructs in vaccines |
MX366154B (es) | 2013-06-21 | 2019-06-28 | Merck Sharp & Dohme | Composiciones de vacuna del virus del dengue y metodos de uso de las mismas. |
ITRM20130458A1 (it) | 2013-08-05 | 2015-02-05 | Internat Ct For Genetic En Gineering And | Vaccino genetico anti-dengue virus basato sugli ectodomini della proteina envelope |
EP3236997B1 (en) * | 2014-12-22 | 2024-05-29 | Merck Sharp & Dohme LLC | Dengue virus vaccine compositions and methods of use thereof |
US20220226401A1 (en) | 2018-09-05 | 2022-07-21 | Takeda Vaccines, Inc. | Dengue vaccine unit dose and administration thereof |
US11464815B2 (en) | 2018-09-05 | 2022-10-11 | Takeda Vaccines, Inc. | Dengue vaccine unit dose and administration thereof |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6455509B1 (en) * | 1996-06-04 | 2002-09-24 | The United States Of America As Represented By The Secretary Of The Navy | Dengue nucleic acid vaccines that induce neutralizing antibodies |
US6962708B1 (en) * | 1997-02-28 | 2005-11-08 | Acambis, Inc. | Chimeric flavivirus vaccines |
BRPI9701774B8 (pt) | 1997-04-11 | 2015-09-29 | Fundação Oswaldo Cruz Fiocruz | cdna mutante e infeccioso do vírus da febre amarela, constructo de dna, vírus recombinante de febre amarela e vacina para humanos contra infecções de febre amarela. |
US6881723B1 (en) * | 1998-11-05 | 2005-04-19 | Powderject Vaccines, Inc. | Nucleic acid constructs |
WO2003102166A2 (en) * | 2002-02-26 | 2003-12-11 | Maxygen, Inc. | Novel flavivirus antigens |
CA2618783A1 (en) | 2005-08-10 | 2007-02-22 | Acambis Inc. | Vaccination against dengue virus infection |
CN101287490B (zh) * | 2005-08-10 | 2013-04-24 | 阿坎姆比斯公司 | 对抗登革热病毒感染的疫苗接种 |
CU23586A1 (es) * | 2005-11-22 | 2010-10-30 | Ct Ingenieria Genetica Biotech | Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus |
EP2462930B1 (en) * | 2006-11-09 | 2017-05-31 | The United States Of America As Represented By The Secretary Of The Navy | Induction of an immune response against dengue virus using prime-boost approach |
KR101686942B1 (ko) * | 2008-01-11 | 2016-12-28 | 이노비오 파마수티컬즈, 인크. | 뎅기 바이러스 다중 서브타입에 대항하는 신규한 백신 |
-
2009
- 2009-10-01 BR BRPI0904020A patent/BRPI0904020B8/pt active IP Right Grant
-
2010
- 2010-08-01 WO PCT/BR2010/000323 patent/WO2011038473A1/pt active Application Filing
- 2010-08-01 PE PE2016001214A patent/PE20161094A1/es unknown
- 2010-08-01 US US13/499,697 patent/US10357558B2/en not_active Expired - Fee Related
- 2010-08-01 CN CN201080052438.4A patent/CN102711817B/zh not_active Expired - Fee Related
- 2010-08-01 PE PE2012000411A patent/PE20121171A1/es active IP Right Grant
- 2010-08-01 EP EP10819756.7A patent/EP2484376A4/en not_active Withdrawn
-
2012
- 2012-03-29 CL CL2012000783A patent/CL2012000783A1/es unknown
- 2012-04-02 CU CU20120057A patent/CU24060B1/es active IP Right Grant
- 2012-04-26 CO CO12069004A patent/CO6541529A2/es unknown
- 2012-05-04 EC ECSP12012131 patent/ECSP12012131A/es unknown
Also Published As
Publication number | Publication date |
---|---|
CU24060B1 (es) | 2014-12-26 |
WO2011038473A8 (pt) | 2012-07-19 |
BRPI0904020A2 (pt) | 2011-06-14 |
CL2012000783A1 (es) | 2013-03-22 |
WO2011038473A1 (pt) | 2011-04-07 |
CN102711817A (zh) | 2012-10-03 |
CO6541529A2 (es) | 2012-10-16 |
ECSP12012131A (es) | 2013-02-28 |
EP2484376A4 (en) | 2014-01-22 |
EP2484376A1 (en) | 2012-08-08 |
PE20161094A1 (es) | 2016-10-22 |
CU20120057A7 (es) | 2013-01-30 |
CN102711817B (zh) | 2016-10-26 |
BRPI0904020B8 (pt) | 2021-05-25 |
US20120251570A1 (en) | 2012-10-04 |
US10357558B2 (en) | 2019-07-23 |
BRPI0904020B1 (pt) | 2019-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20121171A1 (es) | Metodo, kit, plasmido y composicion para inducir una respuesta inmunitaria contra el virus del dengue basandose en vacunas de adn y virus quimericos | |
EA202192570A1 (ru) | Иммуногенные композиции и вакцины, содержащие пептиды и белки вируса африканской чумы свиней, и их применение | |
CO2020004738A2 (es) | Variantes de cápsides de virus adenoasociados y métodos de uso de estas | |
BRPI0913012A2 (pt) | vírus do nilo ocidental/da dengue quiméricos | |
ES2662801T3 (es) | Vacunas atenuadas contra Streptoccocus suis y procedimientos de fabricación y uso de las mismas | |
NO20090194L (no) | Rekombinant viral vaksine | |
JP2009544333A5 (es) | ||
ATE533782T1 (de) | Impfstoffe und immuntherapeutika mit codon- optimiertem il-15 und verwendungsverfahren dafür | |
AR061484A1 (es) | Secuencias de adn vectores proteinas y usos de hemaglutinina de gripe aviar | |
AR087020A1 (es) | Polipeptidos de fusion de relaxina y usos de los mismos | |
PE20160188A1 (es) | Variantes aav y composiciones, metodos y usos para transferencia de gen a celulas, organos y tejidos | |
AR086078A1 (es) | Proteinas de fusion y vacunas de combinacion | |
EA202092990A3 (ru) | Молекула нуклеиновой кислоты, кодирующая коровый белок вируса гепатита в, и вакцина, содержащая указанную молекулу | |
NO20090780L (no) | Human Glp-1 mimetistoff, sammensetninger, fremgangsmater og anvendelser | |
WO2009124312A3 (en) | Consensus sequences of chikungunya viral proteins, nucleic acid molecules encoding the same, and compositions and methods for using the same | |
CL2012000447A1 (es) | Composición o vacuna que comprende un vector viral de un paramixovirus aviar 8 (apmv-8) recombinante; método para producir dicho vector; y uso para preparar medicamento útil para inducir una respuesta inmunológica. | |
Li et al. | Recovery of a chemically synthesized Japanese encephalitis virus reveals two critical adaptive mutations in NS2B and NS4A | |
BR112015005987A2 (pt) | vacina, métodos para induzir uma resposta imune contra um antígeno hbv, para proteção de um sujeito da infeção por hbv, para proteger o sujeito que foi diagnosticado com uma infecção por hbv, para induzir uma resposta imune contra um antígeno do hbv, para proteger um indivíduo da infecção pelo hbv, para proteger um indivíduo que foi diagnosticado com infecção pelo hbv, para proteger um indivíduo da infecção pelo hbv, para proteger um indivíduo que foi diagnosticado com infecção pelo hbv, para proteger um sujeito contra infecção por hbv e para proteger o sujeito que foi diagnosticado com uma infecção por hbv, molécula de ácido nucleico, e, proteína | |
UA108902C2 (uk) | Вірус північноамериканського репродуктивного та респіраторного синдрому свиней (prrs) та його застосування | |
AR080313A1 (es) | Composiciones de virus de moquillo canino (cdv) recombinante y sus usos | |
EA201990717A1 (ru) | Новая вакцина против гриппа свиней | |
AR094725A1 (es) | Parvovirus 5a porcino, métodos de uso y vacuna | |
Lazo et al. | Aiming at the heart: the capsid protein of dengue virus as a vaccine candidate | |
EA200601043A1 (ru) | Промоторы для экспрессии в модифицированном вирусе осповакцины штамма анкара | |
MX2017014417A (es) | Vacunas contra el dengue. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |